karxt schizophrenia news - Search News

FDA Approves 1st New Schizophrenia Drug in Decades

The American Journal of Manage… · 1h

First Schizophrenia Treatment Approved in Decades Targets Cholinergic Receptors

Formally known as KarXT, xanomeline-trospium chloride (Cobenfy) receives approval from the FDA for the treatment of schizophrenia in adults.

Firstpost · 3h

Why approval of KarXT, the first new drug for schizophrenia in decades, is a big deal

After more than three decades, schizophrenia patients have a new treatment option. The US FDA has approved a drug, known as KarXT or Cobenfy. It comes without common side effects such as weight gain a

FDA Approves Potentially Groundbreaking Schizophrenia Drug

On Thursday, the Food and Drug Administration approved Cobenfy, a drug from Bristol Myers Squibb—the first truly novel treatment for schizophrenia in decades.

FDA OKs First-in-Class Antipsychotic for Schizophrenia

The FDA has approved a first-in-class antipsychotic that targets cholinergic receptors without blocking dopamine receptors.

FiercePharma17h

Bristol Myers Squibb's Karuna buyout pays off with FDA approval for novel schizophrenia med Cobenfy

After decades of stagnation in the schizophrenia field, Bristol Myers Squibb’s $14 billion deal for Karuna Therapeutics has ...

5 Schizophrenia Candidates Chasing BMS’ KarXT

As the FDA prepares to render a verdict on BMS’ closely watched schizophrenia drug, BioSpace takes a closer look at the ...

3don MSN

The 'game-changing' treatment for schizophrenia

US poised to approve KarXT as new antipsychotic treatment for disorder, which could offer reduced side-effects ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results